9 results about "Pasteurellosis" patented technology

This invention discloses an indirect ELISA detection kit and method for bovine pasteurellosis, relating to the field of biotechnology. The indirect ELISA kit includes an enzyme-labeled plate coated with an antigen; the amino acid sequence of the antigen is shown in SEQ ID NO.2. The indirect ELISA detection kit constructed in this invention exhibits high specificity and sensitivity; the intra-assay coefficient of variation is between 1.79% and 7.54%, and the inter-assay coefficient of variation is between 2.23% and 6.91%, both below 10%, demonstrating good inter-assay and intra-assay repeatability. In testing 30 clinical samples, the overall concordance rate with the standard "Diagnostic Techniques for Bovine Hemorrhagic Sepsis (GB / T27530-2025)" was 96.67%. The indirect ELISA detection kit demonstrates good overall performance and can be applied to the detection of bovine pasteurellosis in clinical serum samples.

The invention belongs to the field of vaccine microorganisms, and provides a swine pasteurella multocida attenuated strain PmA4-750, which is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: M 20251644. The invention further provides a preparation method of the swine pasteurella multocida attenuated strain PmA4-750. After alternate high-temperature continuous passage, three generations of whole-gene sequencing and pathogenicity contrast tests find that a vaccine candidate strain (PmA4-750 strain) has a section of specific insertion fragment with the length of about 43kb, and 14 genetic variation sites, including 10 InDel (insertion / deletion) and 4 SNP (single nucleotide polymorphism), exist in the vaccine candidate strain. The inserted genes may generate adaptive evolution of strains in the passage process of the strains, so that the pathogenic characteristics of the strains are changed, and the toxicity is promoted to be remarkably reduced. In addition, a piglet immune challenge protection test result shows that the PmA4-750 strain has an immune effect on swine pasteurellosis caused by type A, type D or type B pasteurella multocida. In addition, the invention also discloses a swine pasteurellosis live vaccine and a preparation method thereof.

The invention belongs to the technical field of microorganisms, and particularly relates to rabbit source D-type pasteurella multocida and application thereof. The preservation number of the strain is CCTCC (China Center For Type Culture Collection) NO: M 2024856. The strain induces cellulosic pneumonia, has an application value of constructing a rabbit pasteurellosis animal model, and has good immunogenicity, a whole-cell inactivated antigen can effectively stimulate immune response of a mouse body and induce generation of a high-level antibody, and the strain has the potential of being developed into a vaccine.

This invention discloses a method for preparing and applying a Pasteurella-Bordetella nanovaccine, belonging to the field of biomedical technology. The method includes the following steps: emulsifying epigallocatechin gallate, an antigen aqueous phase, and soybean oil under high-speed shearing, followed by homogenization to form a stable oil-in-water emulsion, which is the Pasteurella-Bordetella nanovaccine. Challenge experiments confirmed that the ESO vaccine achieved a protection rate of up to 90% against Pasteurella multocida and Bordetella bronchiseptica, significantly superior to the 40%-70% protection rate of the aluminum adjuvant group. Simultaneously, it significantly reduced the bacterial load in the lungs, demonstrating excellent clinical protective effects. This invention, through the innovative combination of EGCG and vegetable oil, overcomes the limitations of traditional adjuvants in terms of immunogenicity, safety, and single function, providing a highly efficient and safe new vaccine solution for the prevention and control of Pasteurella multocida and Bordetella multocida infections.

The invention discloses dihydromyricetin copper for treating swine pasteurellosis and a preparation method of the dihydromyricetin copper. According to the method, a synthetic reaction of a complex is carried out in an ethanol-ammonium acetate buffer solution with the pH value of 3.7; the optimal feeding molar ratio of the copper salt solution to the dihydromyricetin is 1.1: 2.0; the optimal reflux reaction time is 30 minutes. The complex is stable in activity and good in antibacterial effect on pig pasteurella multocida. The invention also provides a preparation method of the complex, and the method is simple, easy to control, suitable for large-scale production, high in product yield and high in purity, and is expected to become a medicine for replacing antibiotics to treat swine pasteurellosis.

The invention discloses a preparation method and application of a pasteurization-bordetella nanometer vaccine, and belongs to the technical field of biological medicine. Comprising the following steps: carrying out high-speed shearing emulsification on epigallocatechin gallate, an antigen water phase and soybean oil, and homogenizing to form a stable oil-in-water emulsion, namely the pasteurization-bordetella nano vaccine. A challenge test proves that the protection rate of the ESO vaccine to pasteurella multocida and bordetella bronchiseptica reaches up to 90%, which is obviously superior to the 40-70% protection rate of an aluminum adjuvant group, and meanwhile, the lung bacterium loading amount is obviously reduced, so that the ESO vaccine shows an excellent clinical protection effect. The EGCG and the vegetable oil are innovatively compounded, so that the limitation of the traditional adjuvant in the aspects of immune efficacy, safety and function singleness is broken through, and an efficient and safe novel vaccine solution is provided for prevention and control of pasteurellosis and bordetella disease.

The invention provides a pig lung pasteurization disease management system and method, electronic equipment and a medium, and the system comprises an image obtaining module which is used for obtaining a plurality of groups of original pig lung images; the image processing module is used for performing image processing on each group of original pig lung images to obtain a target lung image; the image recognition module is used for recognizing the target lung image based on a pre-trained Pasteur disease recognition model to obtain a Pasteur disease recognition result; and the result analysis module is used for analyzing the pasteurization disease recognition result and determining a breeding scheme based on the analysis result. The method can improve the recognition efficiency, saves the manpower of manual evaluation, and improves the health level of pig breeding.

The invention discloses a preparation method of dihydromyricetin manganese for treating swine pasteurellosis. According to the method, a synthetic reaction of a complex is carried out in an ethanol-ammonium acetate buffer solution with the pH value of 3.7; the optimal feeding molar ratio of the manganese salt solution to the dihydromyricetin is 1.1: 1.0; the optimal reflux reaction time is 30 minutes. The compound is stable in activity and good in antibacterial effect on pig pasteurella multocida. The invention also provides a preparation method of the compound, and the method is simple, easy to control, suitable for large-scale production, high in product yield and high in purity, and is expected to become a medicine for replacing antibiotics to treat swine pasteurellosis.

The invention discloses a bovine pasteurellosis indirect ELISA (enzyme-linked immuno sorbent assay) detection kit and a detection method, and relates to the technical field of biology. The indirect ELISA kit comprises an ELISA plate coated with an antigen, the amino acid sequence of the antigen is as shown in SEQ ID NO. 2. The indirect ELISA detection kit constructed by the invention is strong in specificity and good in sensitivity; the intra-batch variation coefficient ranges from 1.79% to 7.54%, the inter-batch variation coefficient ranges from 2.23% to 6.91%, both the intra-batch variation coefficient and the inter-batch variation coefficient are lower than 10%, and inter-batch and intra-batch repeatability is good; 30 clinical samples are detected, and the total coincidence rate is 96.67% compared with the cattle hemorrhagic septicemia diagnosis technology (GB / T27530-2025). The indirect ELISA detection kit is good in comprehensive evaluation and can be applied to clinical serum sample detection of bovine pasteurella multocida.